Preparation of pH-sensitive nanogels bioconjugated with shark antibodies (VNAR) for targeted drug delivery with potential applications in colon cancer therapies
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0294874 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Lizbeth A Manzanares-Guevara und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Innovation Department, Centro de Investigación Científica y de Educación Superior de Ensenada (CICESE), Ensenada, Baja California, México. Hauptthemen laut MEDLINE: Antineoplastic Agents, Colonic Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CONACYT MEXICO.
Abstract (Originalsprache)
Cancer is the second leading cause of death worldwide. To combat this disease, novel and specialized therapeutic systems are urgently needed. This is the first study to explore a system that combines shark variable domain (Fv) of new antigen receptor (VNAR) antibodies (hereinafter VNARs), PEGylated nanogels (pH-sensitive poly( N , N -diethylaminoethyl methacrylate, PDEAEM), and the anticancer drug 5-fluorouracil (5-FU) to explore its potential applications in colon cancer therapies. Nanogels were functionalized in a scalable reaction with an N -hydroxysuccinimide (NHS)-terminated polyethylene glycol derivative and bioconjugated with shark antibodies. Dynamic light scattering measurements indicated the presence of monodispersed nanogels (74 to 236 nm). All systems maintained the pH-sensitive capacity to increase in size as pH decreased. This has direct implications for the release kinetics of 5-FU, which was released faster at pH 5 than at pH 7.4. After bioconjugation, the ELISA results indicated VNAR presence and carcinoembryonic antigen (CEA) recognition. In vitro evaluations of HCT-116 colon cancer cells indicated that functionalized empty nanogels are not cytotoxic and when loaded with 5-FU, the cytotoxic effect of the drug is preserved. A 15% reduction in cell viability was observed after two hours of contact with bioconjugated nanogels when compared to what was observed with non-bioconjugated nanogels. The prepared nanogel system shows potential as an effective and site-specific nanocarrier with promising applications in in vivo studies of colon cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Biomedical Innovation Department, Centro de Investigación Científica y de Educación Superior de Ensenada (CICESE), Ensenada, Baja California, México.
- Centro de Graduados e Investigación en Química, Tecnológico Nacional de México/Instituto Tecnológico de Tijuana, Tijuana, Baja California, México.
- Applied Physics Division, Centro de Investigación Científica y de Educación Superior de Ensenada (CICESE), Ensenada, Baja California, México.
ORCID-Profile: Alexei F Licea-Navarro
Förderung
- CONACYT MEXICO
Zitieren
APA
Manzanares-Guevara, L. A., Gasperin-Bulbarela, J., Cabanillas-Bernal, O., Renteria-Maciel, M., Licea-Claverie, A., Méndez, E. R., & Licea-Navarro, A. F. (2024). Preparation of pH-sensitive nanogels bioconjugated with shark antibodies (VNAR) for targeted drug delivery with potential applications in colon cancer therapies. PLOS ONE. https://doi.org/10.1371/journal.pone.0294874
Vancouver
Manzanares-Guevara LA, Gasperin-Bulbarela J, Cabanillas-Bernal O, Renteria-Maciel M, Licea-Claverie A, Méndez ER, et al. Preparation of pH-sensitive nanogels bioconjugated with shark antibodies (VNAR) for targeted drug delivery with potential applications in colon cancer therapies. PLOS ONE. 2024. doi:10.1371/journal.pone.0294874
BibTeX
@article{ManzanaresGuevara2024,
author = {Manzanares-Guevara, Lizbeth A and Gasperin-Bulbarela, Jahaziel and Cabanillas-Bernal, Olivia and Renteria-Maciel, Monserrat and Licea-Claverie, Angel and Méndez, Eugenio R and Licea-Navarro, Alexei F},
title = {Preparation of pH-sensitive nanogels bioconjugated with shark antibodies (VNAR) for targeted drug delivery with potential applications in colon cancer therapies},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0294874}
}
EUVIMED